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Intravital imaging of glioma border 
morphology reveals distinctive 
cellular dynamics and contribution 
to tumor cell invasion
Maria Alieva1,2, Verena Leidgens1,3, Markus J. Riemenschneider4, Christoph A. Klein  5, 
peter Hau  3 & Jacco van Rheenen1,6
the pathogenesis of glioblastoma (GBM) is characterized by highly invasive behavior allowing 
dissemination and progression. A conclusive image of the invasive process is not available. The aim of 
this work was to study invasion dynamics in GBM using an innovative in vivo imaging approach. Primary 
brain tumor initiating cell lines from IDH-wild type GBM stably expressing H2B-Dendra2 were implanted 
orthotopically in the brains of SCID mice. Using high-resolution time-lapse intravital imaging, tumor cell 
migration in the tumor core, border and invasive front was recorded. Tumor cell dynamics at different 
border configurations were analyzed and multivariate linear modelling of tumor cell spreading was 
performed. We found tumor border configurations, recapitulating human tumor border morphologies. 
Not only tumor borders but also the tumor core was composed of highly dynamic cells, with no clear 
correlation to the ability to spread into the brain. Two types of border configurations contributed to 
tumor cell spreading through distinct invasion patterns: an invasive margin that executes slow but 
directed invasion, and a diffuse infiltration margin with fast but less directed movement. By providing a 
more detailed view on glioma invasion patterns, our study may improve accuracy of prognosis and serve 
as a basis for personalized therapeutic approaches.
Glioblastoma (GBM) is one of the most aggressive primary brain tumors, with a median survival time of about 
14.6 months despite maximal therapy1. Besides resection and radiotherapy, Temozolomide, a cytotoxic drug2 and 
Optune, so-called Tumor Treating Fields3,4, remain the only measures that improve outcome.
GBM is hallmarked by a high complexity and heterogeneity5,6, making a deep understanding of its pathogen-
esis challenging. The tumor is driven by a minority of cancer stem-like brain tumor initiating cells (BTIC)7,8, that 
appear to be not only implicated in tumor initiation, but also in recurrence, progression9,10 and resistance to cur-
rent therapy8,11. BTICs and non-stem tumor cell co-exists in vivo and are likely to change dynamically depending 
of the tumor microenvironment12,13. In view of modelling the disease, BTICs are the best available cell population 
to investigate GBM in vitro and in vivo14,15.
The pathogenesis of GBM is manifold and includes highly-invasive behavior that is a main cause behind 
GBM dissemination and progression16,17. There is general agreement that invasion is an early event in GBM 
progression16, where the tumor cells tend to invade individually or in small groups17,18. These infiltrating tumor 
cells lie well beyond the definable margin for maximal resections17,18 giving rise to tumor relapse19. GBM cells are 
thought to preferentially migrate along existing brain structures12,18, however vascular co-option and migration 
along white matter tracts are also important features of glioma cell invasion16,20,21. Tumor borders are not always 
uniform, and several invasion patterns such as single cell invasion18,22 and collective migration with leading and 
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follower cells23,24 have been described. However it is unclear how these patterns correlate to clinically relevant 
macroscopic tumor growth and dissemination18,25.
The reason why a conclusive image of the invasive process in malignant gliomas is still not available is partly 
due to the lack of relevant models. Screens based on partitioned resections from tumor boarder and core26,27 and 
conventional in vitro migration assays28–30 are highly artificial and cannot recapitulate in vivo tumor cell behavior.
The development of intravital microcopy (IVM), a potent tool that allows to perform single-cell resolution 
time-lapse imaging on live animals, has provided new insights into (GBM) tumor cell dynamics22,31–39. To further 
investigate the physiological processes40 underlying GBM cell movement, this study aimed to image and analyze 
distinct GBM invasive growth patterns found in vivo, similar to those observed in patients. We combined an 
orthotopic human BTIC-derived GBM model with real time dynamic high-resolution IVM22,31,35 followed by a 
comprehensive analysis of tumor cell migratory behavior and found that distinct types of tumor border morphol-
ogies present different invasive growth patterns that can contribute to tumor expansive growth.
Results
Distinct tumor border configurations in glioma tumors. To gain insight in glioma cells migratory 
behavior at different tumor border configurations we imaged the in vivo behavior of single BTICs derived from 
GBM patients who had undergone resection15,41. We injected two BTIC cell lines (BTIC-10 and BTIC-12) stably 
expressing a nuclear fluorescent protein (H2B Dendra2) in the brain of NSG mice. To gain visual access to the 
brain and study the invasive behavior at single cell level in vivo, we implanted a chronic cranial imaging win-
dow (CIW) around the injection site35. Upon tumor development, a series of microscopic time-lapse z-stack 
images of all the visible tumor volume were acquired through the CIW at multiple time points with a minimum 
time interval of 45 minutes (Fig. 1a). Tile-scan images revealed distinct tumor border configurations (Fig. 1b). 
Three different patterns of invasion were observed: protruding multicellular groups originating at the interphase 
between the tumor and the brain parenchyma were defined as “invasive margin” (Fig. 1b). Tumor margins show-
ing no protrusions were named “well-defined tumor border” (Fig. 1b). Individual cell migration into the invasive 
area of the brain parenchyma was defined as “diffuse cell infiltration” (Fig. 1b). Similar types of invasion patterns 
can also be found in human glioblastoma biopsy samples (Supplementary Fig. S1). For comparison, cell behavior 
in the tumor core was evaluated (Fig. 1b). Both BTIC cells lines showed the described border configurations 
(Supplementary Fig. S2).
The movement of individual tumor cells in distinct tumor border configurations was determined by tracking 
the migration path over time in 3D reconstructed time-lapse movies (Fig. 2a). Information about migration 
velocity, speed, persistence, and directionality was extracted from the tracks. Although there was variation in 
terms of cell velocity between the different mice, the relative migratory behavior between the different border 
configurations was consistent among them (Supplementary Fig. S2). When we performed a mixed-effects regres-
sion of tumor cell migration away from the tumor border we found that it was uncorrelated to the type of BTIC 
(Suppl. Table 1). Thus, we excluded that the type of BTIC had an impact on the migratory behavior and describe 
pooled data of both BTIC lines in further analysis.
Role of spatial cell arrangements in migratory behavior within the invasive margin. Next, we 
aimed to understand what drives cell migration at the invasive margin. We hypothesized that spatial cellular 
arrangements at the invasive margin define the migration direction of subsequently following cells, as previously 
described23. Within each invasive margin position, we measured the direction correlation between cells leading 
invasion and their followers (Fig. 3a). We did not find clear correlations between the direction of movement of 
invasion leading cells and those following (Fig. 2b). To test the hypothesis that these data point towards a pre-
dominant role of the microenvironment to determine direction and against an individual genetic program of a 
subtype of cells, we re-evaluated our IVM movies and observed that cells spatially rearrange within the invasive 
margin, with leader cells becoming followers and vice versa (Supplementary Movie 1).
To further analyze spatial rearrangements, we compared the proportion of leader and follower cells moving 
towards and away from the tumor. We found that cells located at the leader position more often moved away 
from the tumor core (74%) than towards it, compared to follower cells that moved in both directions (Fig. 3c), 
pointing to the hypothesis that they were most strongly disposed to a microenvironmental gradient that triggers 
invasion42,43. While follower cells showed distinct velocities depending on the direction they moved, with a higher 
velocity when moving away from the tumor core, leader cells did not show such behavior (Fig. 3d).
Next, we analyzed invasion related to anatomical structures within the brain. We observed that BTIC use dif-
ferent routes of invasion along white-matter tracts or blood vessels (Supplementary Fig. 3). We further analyzed 
and compared the behavior of cells that used both routes of migration and found that in both cases the direc-
tion of leader cell invasion did not correlate to the direction taken by follower cells (Supplementary Fig. 4a,b,e). 
Perivascular leader cells had a higher tendency to move away from the tumor core than leader cells within the 
parenchyma (Supplementary Fig. 4c). In addition, perivascular leader cells moved faster than intraparenchymal 
leader cells (Supplementary Fig. 4d).
In summary, these results indicate that leader cells migrate away from the tumor core more often and faster 
when associated to blood vessels.
Cell dynamics at the tumor core. To get a more holistic picture of BTIC fates within our model, we next 
analyzed cell migration in the non-invasive parts of the tumor (Fig. 2a). In contrast to the common believe that 
cells within the tumor core are static22, we observed that from all cancer cells in the tumor core, 23% was motile 
(Fig. 2c) and moved with an average speed of 8 μm/hour (Fig. 2d), a speed even higher than of the cells of the 
invasive front.
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Cell dynamics at the tumor border. We next analyzed the behavior of cells within the different types of 
tumor borders. Here, we determined the mean cell velocity of tracked single cells (cell displacement over time) 
and found that cells, at the well-defined border (4.4 µm/hour) and the diffuse margin (5.2 µm/hour), possessed a 
Figure 1. Tumor border configuration in the interphase between normal brain and tumor core. (a) 
Schematic overview of the experimental setup. Patient derived BTIC lines expressing H2B Dendra2 where 
implanted in the brain of NSG mice. Time-lapse intravital imaging was performed through a CIW to study 
the invasive behavior of single tumor cells. (b) Representative 3D reconstructed tile-scan showing distinct 
tumor border configurations. Shown are H2B expressing BTICs in green, collagen fibers in blue. The dotted 
pink line delineates the tumor core, while the dotted yellow line delineates the tumor cell invasive area. Scale 
bar = 300 μm.
www.nature.com/scientificreports/
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Figure 2. Migratory behavior of tumor cells at different border configurations. (a) Representative still images 
from a time-lapse movie showing migrating tumor cells from different border configurations. Red lines 
highlight individual tumor cell tracks. Scale bar = 100 μm. Corresponding plots show tracks with a common 
origin. (b) Quantification of cell velocity for the indicated border and tumor core configurations. The data is 
shown as mean ± S.E.M. (c) Percentage of motile (cell velocity > 2 μm/hour) and static cells for each condition. 
(d) Speed of motile cells at the indicated border and tumor core configurations. Data is shown as mean ± S.E.M., 
n = 7 mice (BTIC-10 and BTIC-12 lines). (e) Persistence of motile cells at the indicated border and tumor 
core configurations. The data is shown as mean ± S.E.M, n = 7 mice (BTIC-10 and BTIC-12 lines). *p < 0.05, 
**p < 0.01, ***p < 0.0001, one-way ANOVA with Tukey’s post hoc test.
www.nature.com/scientificreports/
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higher velocity than cells from the invasive margin (2.6 µm/hour) (Fig. 2b). Next, we compared the percentage of 
motile cells with a cell velocity > 2 µm/hour in between the tumor core and all kinds of borders and observed a 
higher proportion of motile cells in all border configurations as compared to the tumor core (Fig. 2c), pointing to 
a general more migratory behavior of tumor borders. The speed of motile cells (measure of the actual distance a 
cell covers over time) was highest at the diffuse margin and the well-defined border with 11.6 µm/hour and 12 µm/
hour respectively (Fig. 2d). Cells in the invasive margin were found to be moving more slowly with an average 
speed of 6.8 µm/hour. However, when we analyzed the persistence of movement, we discovered that cells from the 
invasive margin moved in the most persistent fashion of higher than 0.36, a number that was previously consid-
ered to be representative for random walk44.
Since directionality is an important feature of invasion, we analyzed the directionality patterns in each type 
of border configuration. We observed disperse directionality patterns in all subtypes (Supplementary Fig. S5), 
with cells migrating towards the parenchyma, while other cells migrated towards the tumor core, or parallel 
to the tumor border (Fig. 2a, Supplementary Movie 1). Moreover, we observed cells that changed migration 
directionality over time (Fig. 2a, Supplementary Movie 1). To assess whether a particular migration behavior is 
favored within one of the border configurations, we plotted the migration path of all the cells from different posi-
tions in a wind rose plot (Fig. 4a). Here, we found the most directed and invasive pattern in the invasive margin 
configuration.
To identify the velocity and proportion of phenotypically relevant invading and retreating cells, we meas-
ured the perpendicular cell displacement relative to the tumor margin (Fig. 4b). We found that the proportion 
of invasion was balanced at all border configurations with only a slight prevalence of invading cells (Fig. 4c). 
The diffuse margin harbored the highest proportion of invading cells (61.5%), followed by the invasive margin 
(54.4%) (Fig. 4c). Moreover, when we compared the velocity of the invading and retreating cells we found that 
invading cells moved faster than retreating cells at both the invasive margin and the diffuse margin, but not at the 
well-defined border (Fig. 4d).
Figure 3. Role of spatial cell arrangements in invasive margin migratory behavior. (a) Schematic representation 
how the correlation of direction between leader and follower cells of the invasive margin was quantified. (b) 
Quantification of direction correlation between leader and follower cells. n = 7. Black squares show BTIC-10 
line. White squares show BTIC-12 line. nsp > 0.05, one sample Student’s t, hypothetical value = 0. (c) Percentage 
of invading and regressing cells for each condition, n = 7 (BTIC-10 and BTIC-12). (d) Quantification of Y-axes 
displacement for the invading/regressing cells of each condition, n = 7 (BTIC-10 and BTIC-12). *p < 0.05, 
Student’s t test. For leader and follower cells invading cells versus receding cells were tested.
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Finally, to depict if all areas within a specific border configuration follow the same phenotypic behavior, we 
assessed the overall displacement of the center of mass perpendicular to the tumor margin (COMy) (Fig. 4e). 
In all border configurations, we found positions moving towards and away from the tumor border (Fig. 4e), 
Figure 4. Direction of cell movement at different tumor border configurations. (a) Wind rose plot representing 
the percentage of cells migrating in the direction of a leaflet for each tumor border configuration. Color 
scale indicates migration speed, n = 7 (BTIC-10 and BTIC-12). (b) Schematic representation of Y-axes cell 
displacement quantification. (c) Percentage of invading and regressing cells for each condition, n = 7 (BTIC-
10 and BTIC-12). (d) Quantification of the Y-axes velocity for invading and regressing cells of each condition, 
respectively, n = 7 (BTIC-10 and BTIC-12), *p < 0.05, Student’s t test. For each border configuration invading 
cells versus regressing cells were tested. (e) Tukey-style whiskers plot of the center of mass displacement of 
individual positions of each condition. Boxes indicate the interquartile range, crosses indicate the mean, 
and dots indicate outliers. n = 7 (BTIC-10 and BTIC-12), *p < 0.05, one sample Student’s t test, hypothetical 
value = 0. When the center of mass does not change in respect to its initial position it is considered to be 0. The 
one sample Student´s t test determines if the mean of the center of mass displacement (COMd) of the positions 
belonging to the distinct border types is different from 0. COMd > 0: overall the cells in this type of position 
move towards the tumor core. COMd < 0: overall the cells in this type of position move away from the tumor 
core. (f) Schematic illustration of the model showing cell dynamics at different tumor border configurations.
www.nature.com/scientificreports/
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indicating that not all the regions of a tumor are in continuous expansion. Our results showed that for the 
well-defined border configuration the mean COMy was close to zero, indicating that this type of configuration, 
although very dynamic within the position (Fig. 2a), does not contribute to cell spreading away from the tumor. 
However, both the diffuse and invasive margin showed a mean COMy shifted towards the brain parenchyma 
(Fig. 4e), emphasizing that these configurations may drive tumor cell spreading away from the tumor.
To further confirm this observation, we used a multivariate linear model to more accurately evaluate the 
association of COMy with factors such as mean velocity of invading cells, mean velocity of retreating cells and 
their interaction with variables such as frequency of invading cells, configuration type and BTIC type (Suppl. 
Table 2). Our model shows that for each position the velocity of invading cells was the strongest predictor of 
tumor expansion (COMy shift towards the brain parenchyma) and was independent of the BTIC cell line. The 
velocity of invading cells showed interaction effects with two other predictors (Supplementary Fig. 6), namely 
frequency of invading cells and border configuration type. We consolidated variation to these predictors: with a 
high proportion of invading cells, the velocity of invading cell has a higher impact on tumor expansion (COMy); 
the velocity of invading cells has a higher impact on cell spreading and at the invasive margin and at the diffuse 
border (Supplementary Fig. 6a).
Since our analysis showed that cells at the invasive margin have a lower cell velocity (Figs 2b and 4d), this 
factor alone could not explain a similar effect on cell spreading at the invasive margin and at the diffuse border as 
shown in Fig. 4e. Therefore, we analyzed the distribution of the frequency with which cells were invading within 
each position for each configuration type and found that the invasive margin showed more positions with a high 
frequency of invading cells compared to the diffuse margin (Supplementary Fig. 6b).
Combined, these data indicate that the diffuse margin and invasive margin contribute to cell spreading and 
tumor expansion through two different mechanisms: a higher speed for the first, and a higher proportion of 
invading cells for the second.
Discussion
In contrast to glioblastoma morphology, tumor cell dynamics within GBM is not well understood. We combined 
an orthotopic GBM model, time-lapse in vivo microscopy of human brain tumor initiating cells through a cranial 
window, and in-depth analysis of tumor cell spreading to acquire a better insight of GBM tumor cells dynamics 
within their environment on multiple layers.
Using this approach, we delineated tumor border configurations conformed by two different types of inva-
sion represented by cells in the invasive margin and diffuse infiltration pattern; and one pattern that, although 
dynamic, seems to be non-invasive, the well-defined tumor border pattern. We discovered that, in contrast to 
the other patterns45, cells from the invasive margin moved with lower velocity and speed, but in the most persis-
tent fashion. At the diffuse margin cells moved less persistently but also contributed to cell spreading and tumor 
expansion through a higher speed of migration. Moreover, we found that not all regions that show tumor cell 
migration actually contribute to tumor cell invasion. GBM cells in the tumor well defined border, a region gener-
ally thought to be static22, are also extremely dynamic, but do not contribute to invasion as their movement shows 
a highly undirected pattern. This highlights the importance of this study, indicating that a more comprehensive 
analysis of GBM including morphological and dynamic data may allow deeper insights in the complex mech-
anism of invasion. In contrast, studies that looked solely on tumor cell migration speed, or were performed in 
vitro, models where tumor cells lack microenvironmental cues for directed migration, do not fully elucidate this 
heterogeneity30,46.
Glioma cells have previously been reported to use different routes of invasion such as intraparenchymal inva-
sion along white-matter tracks16,21 or invasion along blood vessels16. In line with this, in our model, perivascular 
leader cells had also a higher tendency to move away from the tumor core than cells within the parenchyma, and 
to move faster. These data correspond well to published data, where individually migrating cells, collective strands 
extending along blood vessels or white matter tracts, and multicellular networks of interconnected glioma cells 
were found22,45,47–49. However, this is the first piece of work that analyzed single-cell dynamics of patient derived 
tumor cells in vivo at different tumor border and invasive front areas corresponding to the morphologies found 
in patients.
It has been previously described that collectively moving cells can either have a specific role defined by their 
position in the cellular stream, or dynamically change position with any cell from the group with the ability to 
drive migration23. Against our expectation, we did not find clear correlations between the direction of movement 
of invasion leading cells and those following. Our results show that in our model tumor cells can dynamically 
exchange position in the collective cell stream indicating that their behavior may be more dependent of microen-
vironmental influences than of genetic predisposition. Cells located at the leader position more often moved 
away from the tumor core than towards it, compared to follower cells that moved in both directions. This possibly 
points to the hypothesis that leader cells were most strongly disposed to a microenvironmental gradient that trig-
gers invasion50–52, probably due to distinct microenvironmental structures45,53 or gradients of chemoattractants50. 
Moreover, since we found migratory cells in all areas of the tumor, it is likely that all cells have an intrinsic capac-
ity to migrate, however only some actually contribute to invasion due to microenvironmental cues.
The fact that tumor cells move bidirectionally indicates that tumor cells may receive chemotactic signals from 
both the tumor core and the tumor microenvironment. Indeed, studies based on brain slices engrafted with 
tumor spheres showed a cell fraction with a highly invasive morphology that interacted with the tumor core54–56. 
In addition, ex vivo and in vivo studies using IVM have also shown that tumor cells that are integrated into 
functional connective networks respond to tumor core removal or injury by repopulating the injured area54,57. 
We have also found that tumor biopsy-like injury changes tumor cell migratory capacity and increases tumor 
cell migration speed31, all contributing to the hypothesis that invasion is highly dependent on the environment. 
Another potential driver of glioma tumor cell migration is the direct movement of stromal cells. Although there 
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is no evidence so far that that brain parenchymal cells can directly drive tumor cell migration, in squamous cell 
carcinoma, fibroblasts have shown to lead collective migration of tumor cells58. Moreover immune cells, such as 
macrophages, have shown to associate with breast tumor cells, drive their migration towards blood vessels and 
facilitate their intravasation59. The possibility of parenchymal brain cells such as e.g. microglia as direct drivers of 
glioma cell migration still needs to be explored.
In summary our work is the first analytical study that correlates distinct tumor border patterns that can be 
found on histological sections with particular tumor cell dynamics. It not only fosters the understanding of single 
cell invasion, but possibly also of distant metastasis and re-population of the primary tumor site, both mech-
anisms that significantly influence the prognosis of patients with GBM. Our long-term goal is to correlate the 
analysis of tumor morphology with the dynamics of tumor cell movement to get a more complete picture of GBM 
invasion and to therefore improve the prognostic evaluation of GBM and to possibly develop novel therapeutic 
approaches. Future work should be directed to analyze invasive behavior of a much larger cohort of distinct 
patient-derived tumor cell lines, in order to confirm our results and to allow correlations with morphological 
and possibly prognostic features. Since it is known that the adaptive immune system can also influence tumor 
migratory behavior18,60, it might be worth to use humanized tumor mouse models to assess the role of the human 
immune microenvironment on tumor cell behavior.
Materials and Methods
Tumor cell lines. We used previously established primary brain tumor initiating cell lines (BTIC)-10 and 
-12 derived from patients with IDH wild type glioblastoma as described15,41. The Department of Neuropathology, 
University of Regensburg (MJR), verified the patients’ diagnoses and WHO grade.
Tumor cells were maintained in RHB-A (Y40001, Takara), supplemented with 20 ng/ml of EGF (130097751), 
bFGF (130093842) (both Miltenyi Biotech), and 50 U (v/v) Penicillin/0.05% (v/v) Streptomycin (P4333) 
(Sigma-Aldrich) at 37 °C, 5% CO2, 95% humidity in a standard tissue culture incubator. Progenitor features of 
BTICs were verified by clonogenicity assays, flow cytometry (CD133, CD15, CD44, A2B5), immunocytochemis-
try (Nestin, Sox2, GFAP), and tumor take in an immunocompromised mouse model (female NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ). BTICs were lentivirally transduced to achieve stable expression of the nuclear fluorescent pro-
tein H2B Dendra2, as described61.
The ethics board of the University of Regensburg, Germany, approved the use of human material for this study 
(No° 11-103-0182) and all patients gave written informed consent. All methods were performed in accordance 
with the relevant guidelines and regulations.
Animals. Non-obese diabetic SCID IL-2 receptor gamma chain knockout (NSG) mice 8 to 12 weeks post 
partum were used for the experiments. Mice were housed in an individually ventilated cage and received food 
and water ad libitum. All experiments were carried out in accordance with the guidelines of the Animal Welfare 
Committee of the Royal Netherlands Academy of Arts and Sciences, the Netherlands. The experimental protocols 
used in this manuscript were approved by the Centrale Commissie Dierproeven (CCD) and the Instantie voor 
Dierenwelzijn (IvD).
Cranial imaging window (CIW) surgery and tumor cell injection. CIW surgery and tumor cell injec-
tion were performed at the same day as described31,62. Briefly, mice were sedated with Hypnorm (Fluanison [neu-
roleptic] + Fentanyl [opioid]) (0.4 ml/kg) + Midazolam [benzodiazepine sedative] (2 mg/kg) at a dose of 1:1:2 in 
sterile water and mounted in a stereotactic frame. The head was secured using a nose clamp and two ear bars. The 
head was shaved and the skin was cut in a circular manner. The mouse was placed under a stereo-microscope to 
ensure precise surgical manipulation. The periosteum was scraped and a circular groove of 5 mm diameter was 
drilled over the right parietal bone. The bone flap was lifted under a drop of cortex buffer (125 mM NaCl, 5 mM 
KCl, 10 mM glucose, 10 mM HEPES buffer, 2 mM MgSO4 and 2 mM CaCl2, pH 7.4) and the dura mater was 
removed. Gelfoam sponge (Pfizer) was used to stop bleeding. (Supplementary Fig. 7).
Next, 1 × 105 BTIC H2B-Dendra2 cells suspended in 3 μl of PBS were injected stereotactically using a 10 μl 
Hamilton syringe with a 2 pt style in the middle of the craniotomy at a depth of 0.5 mm. The exposed brain was 
sealed with silicone oil and a 6 mm coverslip glued on top. Dental acrylic cement (Vertex) was applied on the skull 
surface, covering the edge of the coverslip and a stainless steel ring was glued around the coverslip to provide fix-
ation to the microscope. A single dose of 100 μg/kg of buprenorphine (Temgesic, BD pharmaceutical limited) was 
administered. Mice were closely monitored twice per week for behavior, reactivity and appearance.
Intravital imaging. Mice were imaged as previously described31. In short, mice were sedated and placed 
face-up in a custom-designed imaging box. Time-lapse images of the entire tumor volume were acquired for a 
maximum of 13 hours. The minimal time interval between serial images was set to 45 minutes. For tile-scans, 
images of the complete z-stack of the tumor were acquired to a depth of 300 μm, with a step size of 3 µm (typi-
cally 70–100 images in each z-stack). In a group of 4 mice, blood vessels were imaged by intravenous injection of 
70 kDa Dextran–Texas Red (Invitrogen Life Technologies) or 2.000.000 kDa Dextran-Rhodamine (Thermofisher 
scientific).
Imaging was performed on an inverted Leica SP8 multiphoton microscope with a chameleon Vision-S 
(Coherent Inc., Santa Clare, CA, www.coherent.com), equipped with a 25 x water objective (HCX IRAPO NA0.95 
WD 2.5 mm) with four HyD detectors: HyD1 (560–650 nm), HyD2 (500–550 nm), HyD3 (455–490 nm), and 
HyD4 (<455 nm). Images were acquired at a wavelength of 960 nm, where H2B Dendra2 as well as both Dextran 
reagents showed sufficient signal intensity. Collagen (second harmonic generation) was detected using HyD4, 
H2B-Dendra2 was detected with HyD2 and Dextran reagents were detected with HyD1. Scanning was performed 
in a bidirectional mode at 400 Hz and 12 bit, with a zoom of 1 × , 512 × 512 pixels.
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Image processing and analysis. For 3D visualization, shift correction, rendering and data analysis 
time-lapse movies were processed with Imaris (Bitplane, Switzerland). The Spot Analysis module was used for 
semi-automated tracking of cell motility in three dimensions and for shift correction. Data containing the coor-
dinates of each cell, the values of cell direction, speed (per time unit) and velocity (the vector of movement) was 
exported and processed and plotted in GraphPad or R. As the animal’s pulse and breathing can cause motion arti-
facts, we decided that only cells with a velocity (displacement) more than 2.0 µm/hour were classified as motile.
Regions with distinct patterns of invasion were defined as described above by visual assessment of the first 
frame of the movies. Only regions with a clear invasive pattern were included in the analysis.
The windrose plot representing cell direction and speed was created using R package “openair”63. To measure 
the individual cell and center of mass displacement perpendicular to the tumor border the ‘Chemotaxis and 
Migration Tool’ (Ibidi GmbH) was used64. The results of Imaris tracking were converted in 2D along the x and y 
axes and directly imported into the ‘Chemotaxis and Migration Tool’ software tool. The cell trajectories were all 
extrapolated to (x, y) = 0 at time 0 h (Fig. 2a) to visualize the trajectories of each cell with a common origin. Next 
the cell trajectories were rotated for each position using “Data rotation” tab of the software in order to get the 
tumor margin parallel to the x axis (as in Fig. 4b). The tumor margin was defined as the tangent drawn to the main 
tumor mass. For each cell trajectory the angle of cell displacement vector in respect to the x axes (tumor border) 
was extracted using the ‘Chemotaxis and Migration Tool’. Finally individual cell displacement perpendicular to 
the tumor border was measured as:
Y Cell velocity anglesin( )axes displacement relative to tumor boder= ×
The spatial average of all cell positions was used to measure the center of mass displacement perpendicular to 
the tumor border. For each position the difference in the center of mass along the Y axes between its initial value 
and that at the end of the experiment was measured by means of the ‘Chemotaxis and Migration Tool’. This meas-
ure represented per unit of time was termed the displacement of center of mass (COMy), where n is the number 
of cells per individual position:
∑ ∑= = == =M n y M n y
1 ( ) (0); 1 ( )start i
n
i start end i
n





3D tile scan projections were used for illustration of different border configurations. For illustration of tumor 
cell migration, 3D images were tracked manually with an ImageJ plugin (“MTrackJ” Rasband, W.S., ImageJ, U.S. 
NIH, Bethesda, Maryland, USA).
The identities of leader and follower cells were defined at the first frame of the time-lapse and were maintained 
through all the movie. The first cells protruding from an invasive margin morphology were defined as “leader”. 
All the consequent cells from the invasive margin were defined as “follower”. The direction correlation between 
leader and follower cells of the invasive margin was calculated as the cosine of the angle of the leader cell and all 
the follower cell paths (Fig. 3a). Values close to 1 indicate correlation of direction, while values close to −1 indi-
cate opposite direction correlation.
As i.v. injected Dextran reagents leak out of the vessels in the course of time, blood vessel structure from the 
first time point was applied to all time points for illustration of the blood vessels in the time-lapse stills.
Patient glioblastoma samples. Archives of the Department of Neuropathology, University Hospital 
Regensburg, were reviewed for glioblastoma cases sampled with parts of the infiltrative rim and representing 
a spectrum of infiltration patterns observed in the mouse glioblastoma window model. Immunohistochemical 
staining was performed in context of the routine diagnostic work-up of the samples following a standard proto-
col65. Antibodies used were as follows: GFAP (Clone 6F2), Dako #M0761, 1:200 dilution; p53(Clone BP53-12) 
Santa Cruz Biotechnology #SC-263, 1:2000 dilution; Ki-67(Clone MIB-1) Dako #M7240, 1:200 dilution.
Statistical analysis. For all normally distributed measurements, the Student’s t test (comparison of two 
mean values) or one-way ANOVA (when >2 means were compared) were used to determine significance, set to 
p < 0.05. Post-hoc tests were performed with p values < 0.05. All p values were two-tailed. Levels of significance 
were set as follows: nsp > 0.05, *0.05 ≤ p > 0.01, **0.01 ≤ p > 0.001, ***0.001 ≤ p > 0.0001, ****p ≤ 0.0001. Error 
bars are presented as ± S.E.M. All statistical analysis were performed using GraphPad Prism software (version 6, 
GraphPad Software, USA).
Data Availability
The authors declare that all data supporting the findings of this study are available within the article and its Sup-
plementary Information files, or from the corresponding author (MA) upon request.
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